Influenza vaccines based on virus-like particles.

Influenza vaccines based on virus-like particles.
复制标题

基于病毒样颗粒的流感疫苗。

DOI:
10.1016/j.virusres.2009.04.005
复制
发表时间:
2009-08
期刊:
影响因子:
5
通讯作者:
Compans, Richard W.
Compans, Richard W.
中科院分区:
医学3区
文献类型:
--
作者:
Kang, Sang-Moo;Song, Jae-Min;Quan, Fu-Shi;Compans, Richard W.

文献摘要

参考文献

被引文献

相似文献

病毒结构蛋白的同时表达可以在病毒生命周期中通过自组装过程产生病毒样颗粒(virus-like particles,VLP),即使在缺乏基因组物质的情况下。利用VLP与天然病毒粒子的结构和形态相似性,VLP已被建议作为新病毒疫苗的有前途的平台。鉴于大流行的威胁,流感病毒颗粒最近被开发为新一代非蛋细胞培养衍生的候选疫苗,用于对抗流感感染。用含有血凝素(HA)或HA和神经氨酸酶(NA)的VLP接种的动物被保护免于致死性流感感染导致的发病率和死亡率。流感病毒VLP作为一个很好的模型系统的包膜病毒了解VLP诱导保护性免疫的性质。本文简要介绍了由糖蛋白组成的脂双层结构的流感病毒VLP的特性,并对流感病毒VLP作为季节性流感病毒和大流行性流感病毒的候选疫苗的研究进展进行了综述。此外,还讨论了流感病毒性颗粒疫苗接种诱导的保护性免疫相关性。
The simultaneous expression of structural proteins of virus can produce virus-like particles (VLPs) by a self-assembly process in a viral life cycle even in the absence of genomic material. Taking an advantage of structural and morphological similarities of VLPs to native virions, VLPs have been suggested as a promising platform for new viral vaccines. In the light of a pandemic threat, influenza VLPs have been recently developed as a new generation of non-egg based cell culture-derived vaccine candidates against influenza infection. Animals vaccinated with VLPs containing hemagglutinin (HA) or HA and neuraminidase (NA) were protected from morbidity and mortality resulting from lethal influenza infections. Influenza VLPs serve as an excellent model system of an enveloped virus for understanding the properties of VLPs in inducing protective immunity. In this review, we briefly describe the characteristics of influenza VLPs assembled with a lipid bilayer containing glycoproteins, and summarize the current progress on influenza VLPs as an alternative vaccine candidate against seasonal as well as pandemic influenza viruses. In addition, the protective immune correlates induced by vaccination with influenza VLPs are discussed.
DOI: 10.1371/journal.pone.0001501
发表时间: 2008-01-30
期刊: PloS one
影响因子: 3.7
作者:
Bright RA;Carter DM;Crevar CJ;Toapanta FR;Steckbeck JD;Cole KS;Kumar NM;Pushko P;Smith G;Tumpey TM;Ross TM
通讯作者: Ross TM
DOI: 10.1128/jvi.00050-06
发表时间: 2006-09-01
影响因子: 5.4
作者:
Buonaguro, L.;Tornesello, M. L.;Buonaguro, F. M.
通讯作者: Buonaguro, F. M.
DOI: 10.1016/j.vaccine.2007.05.052
发表时间: 2007-08-10
期刊: VACCINE
影响因子: 5.5
作者:
Buonaguro, L.;Devito, C.;Buonaguro, F. M.
通讯作者: Buonaguro, F. M.
DOI: 10.1128/jvi.63.4.1549-1557.1989
发表时间: 1989-04-01
影响因子: 5.4
作者:
LANFORD, RE;LUCKOW, V;SUMMERS, MD
通讯作者: SUMMERS, MD
DOI: 10.1016/0168-1702(85)90006-1
发表时间: 1985-01-01
期刊: VIRUS RESEARCH
影响因子: 5
作者:
CARROLL, SM;PAULSON, JC
通讯作者: PAULSON, JC